Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 24.65
-0.15 (-0.60%)
At close: Feb 13, 2026
Jiangsu CoWin Biotech Revenue
Jiangsu CoWin Biotech had revenue of 52.46M CNY in the quarter ending September 30, 2025, with 68.47% growth. This brings the company's revenue in the last twelve months to 167.17M, up 41.46% year-over-year. In the year 2024, Jiangsu CoWin Biotech had annual revenue of 125.88M, down -26.54%.
Revenue (ttm)
167.17M
Revenue Growth
+41.46%
P/S Ratio
16.21
Revenue / Employee
200.68K
Employees
770
Market Cap
2.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125.88M | -45.47M | -26.54% |
| Dec 31, 2023 | 171.34M | -350.26M | -67.15% |
| Dec 31, 2022 | 521.60M | 183.14M | 54.11% |
| Dec 31, 2021 | 338.46M | 105.25M | 45.13% |
| Dec 31, 2020 | 233.21M | 159.27M | 215.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Shanghai Serum Bio-Technology | 196.76M |